研究称,堕胎药丸并发症比林业发展局报告高22倍,引发了安全审查电话。 Study claims abortion pill complications are 22 times higher than FDA reports, prompting safety review calls.

道德与公共政策中心的一项新研究表明,10.93%的堕胎药丸(mifeprístone)与严重并发症有关,比林业发展局报告的不到0.5%的堕胎率高出22倍。 A new study by the Ethics and Public Policy Center claims that the abortion pill, mifepristone, is linked to serious complications in 10.93% of cases, which is 22 times higher than the FDA's reported rate of less than 0.5%. 这项研究分析了865 000例堕胎数据,发现败血症、感染和出血率较高。 The study analyzed data from over 865,000 abortions and found higher rates of sepsis, infections, and hemorrhaging. 这些调查结果促使要求林业发展局审查该药物的安全议定书并考虑更严格的准则。 The findings have prompted calls for the FDA to review the drug's safety protocols and consider stricter guidelines.